|
Hardman & Co Research
Hardman & Co Research on International Biotechnology Trust (IBT): Low FDA activity may drive further M&A
IBT was established in 1994 to provide institutional and retail investors with the opportunity to participate in global biotechnology and life science companies, from venture-stage early drug discovery via venture capital funds (SV Health Investors) through to global, multinational biotechnology companies. The trust’s main aim is to generate capital growth, while minimising risk, through a diversified portfolio and an experienced investment team. Over the last five years, IBT’s NAV per share has increased 25%, while the share price has increased 32% over the same period – the superior returns generally reflected by a reduction in the share price discount.
Please click on the link below for the full report:
If you are interested in meeting the company, you can register your interest by clicking on the above link
Hardman & Co Research can still be accessed for free after MiFID II. Please to read the statement. About Hardman & Co: Hardman Research Ltd, trading as Hardman & Co, is an appointed representative of Capital Markets Strategy Ltd and is authorised and regulated by the Financial Conduct Authority; our FCA registration number is 600843. Hardman Research Ltd is registered at Companies House with number 8256259. Attention is drawn to the important disclaimers at the end of the report.
Dissemination of a CORPORATE NEWS, transmitted by EQS Group. |
1507847 08-Dec-2022
